Bexlosteride
Bexlosteride is a steroidal antiandrogen that was never marketed. It acts as a selective inhibitor of the enzyme 5α-reductase, an enzyme that converts testosterone into the more potent androgen dihydrotestosterone (DHT). Bexlosteride is selective for the type 1 isoenzyme of 5α-reductase, and is able to prevent the conversion of testosterone to DHT in certain parts of the body, including the skin and the prostate gland.
Pharmacology[edit | edit source]
Bexlosteride, like other 5α-reductase inhibitors, prevents the metabolic conversion of testosterone to DHT. This action has the effect of reducing the amount of DHT in the body, which can be beneficial in the treatment of conditions that are caused or exacerbated by excessive levels of DHT, such as benign prostatic hyperplasia (BPH) and androgenic alopecia (male-pattern baldness).
The mechanism of action of bexlosteride involves the inhibition of the type 1 isoenzyme of 5α-reductase. This isoenzyme is primarily found in the skin and the prostate gland, and is responsible for the majority of the conversion of testosterone to DHT in these tissues. By inhibiting this enzyme, bexlosteride is able to reduce the levels of DHT in these tissues, which can help to alleviate the symptoms of conditions such as BPH and androgenic alopecia.
Clinical significance[edit | edit source]
Although bexlosteride was never marketed, it has been the subject of scientific research due to its potential applications in the treatment of conditions such as BPH and androgenic alopecia. The selective inhibition of the type 1 isoenzyme of 5α-reductase by bexlosteride may offer advantages over non-selective 5α-reductase inhibitors, such as a reduced risk of side effects.
However, the development of bexlosteride was ultimately discontinued, and it is not currently available for medical use. Despite this, research into the pharmacology and potential applications of bexlosteride continues, and it remains a topic of interest in the field of endocrinology and pharmacology.
See also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
